Fund Management at Engine No 1’s Alnylam Pharmaceuticals ALNY Stock Holding History

Fund Management at Engine No 1’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,789	Closed	-$317K	–	22
2023 Q3	$317K	Buy	1,789 +167	+10%	+$31.9K	0.05%	320
2023 Q2	$308K	Buy	1,622 +130	+9%	+$25.8K	0.06%	328
2023 Q1	$299K	Buy	1,492 +137	+10%	+$28.8K	0.06%	314
2022 Q4	$322K	Buy	1,355 +202	+18%	+$43.1K	0.08%	260
2022 Q3	$231K	Buy	+1,153	New	+$220K	0.07%	278

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fund Management at Engine No 1's ALNY Position: Q4 2023 in Review

Fund Management at Engine No 1 sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2023, closing a stake of 1,789 shares — an estimated $317K sold.

Fund Management at Engine No 1 first reported a position in ALNY in Q3 2022 and held it in 5 quarters. The position peaked at $322K in Q4 2022. 498 funds tracked by Wall St. Rank hold ALNY as of Q4 2023.

Fund Management at Engine No 1 reported no remaining Alnylam Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Fund Management at Engine No 1 sold 1,789 Alnylam Pharmaceuticals shares in Q4 2023, an estimated $317K.
Fund Management at Engine No 1 first reported a position in Alnylam Pharmaceuticals in Q3 2022 and held it in 5 quarters.
Fund Management at Engine No 1's Alnylam Pharmaceuticals position peaked at $322K in Q4 2022.
498 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2023.

Based on Fund Management at Engine No 1's 13F filing for Q4 2023.